Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

Rhea-AI Summary

Cytokinetics, Incorporated (Nasdaq: CYTK) announced that results from the REDWOOD-HCM analysis of aficamten will be presented at the ASE 33rd Annual Scientific Sessions from June 10-13, 2022. The presentation, titled "Early Cardiac Structural and Functional Reverse Remodeling in Obstructive Hypertrophic Cardiomyopathy After 10 Weeks of Aficamten Therapy," will be delivered by Dr. Theodore Abraham on June 11, 2022. A recording will be available on-demand starting July 11, 2022.

Positive

• Presentation of new data on aficamten at a prestigious cardiology conference may enhance visibility and investor interest.
• Ongoing clinical trials for aficamten demonstrate Cytokinetics' commitment to advancing innovative therapies in cardiology.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) relating to the effect of treatment with aficamten on measures of cardiac structure and function will be presented in a poster presentation at the American Society of Echocardiography (ASE) 33^rd Annual Scientific Sessions, taking place in person in Seattle and online from June 10, 2022 – June 13, 2022. A recording of the presentation will be available on-demand for registered attendees starting July 11, 2022 at 10:00 AM ET.

Title: Early Cardiac Structural and Functional Reverse Remodeling in Obstructive Hypertrophic Cardiomyopathy After 10 Weeks of Aficamten Therapy: Analyses from REDWOOD-HCM
Presenter: Theodore Abraham, M.D., FACC, FASE, Professor of Medicine, Department of Cardiology, University of California, San Francisco; Co-director, UCSF HCM Center of Excellence; Director, UCSF Adult Cardiac Echocardiography Laboratory
Date: June 11, 2022
Topic: Echocardiography in Myocardial Disease (HCM, Amyloidosis, Sarcoidosis, Chagas)
Session Title: President’s Circle Poster Session
Session Time: 4:00-6:00 PM PT
Location: Echo Expo

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our other clinical trials, statements relating to the potential benefits of omecamtiv mecarbil, aficamten, or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(650) 624-3071

FAQ

What are the key details about Cytokinetics' presentation at the ASE 2022?

Cytokinetics will present results from the REDWOOD-HCM analysis on June 11, 2022, focusing on aficamten and its effects on cardiac remodeling.

When will the presentation of <em>aficamten</em> be available for on-demand viewing?

The presentation recording will be available on July 11, 2022, at 10:00 AM ET.

What is the significance of the REDWOOD-HCM analysis for Cytokinetics (CYTK)?

The REDWOOD-HCM analysis may provide critical insights into the efficacy of aficamten in treating obstructive hypertrophic cardiomyopathy, influencing investor sentiment.